Sonrotoclax | Bcl-2 inhibitor | Probechem Biochemicals

Chemical Structure : Sonrotoclax

CAS No.: 2383086-06-2

加入收藏

Sonrotoclax (BGB-11417, BGB11417)

货号: PC-21675Not For Human Use, Lab Use Only.

Sonrotoclax (BGB-11417) is a potent, selective and second-generation BCL2 inhibitor with IC50 of 0.014 nM and SPR KD value of 0.046 nM, overcomes BCL2 G101V mutation-induced venetoclax resistance.

规格	价格	库存
1 mg	￥3280	In stock
5 mg	￥6980	In stock
10 mg		Get quote
25 mg		Get quote

获取报价单

* 请选择数量再加入购物车

or Bulk Inquiry

大包装，大折扣！

E-mail: sales@probechem.com

Tech Support: tech@probechem.com

生物&药学活性

Sonrotoclax (BGB-11417) is a potent, selective and second-generation BCL2 inhibitor with IC50 of 0.014 nM and SPR KD value of 0.046 nM, overcomes BCL2 G101V mutation-induced venetoclax resistance.
Sonrotoclax inhibits the BCL2-BAK interaction with IC50 of 0.014 nM, exhibiting a 14-fold increase in potency compared to venetoclax (Cat#PC-49764).
Sonrotoclax also demonstrates better selectivity than venetoclax for other Bcl-2 family members, particularly BCL-xL (2000-fold), which is related to platelet toxicity and dose-limiting thrombocytopenia.
Sonrotoclax exhibits superior potency compared to venetoclax in different hematological cancer cells and xenograft models.
Sonrotoclax exhibits IC50 of 7.7 nM for BCL2 G101V mutant, RS4;11 cells, venetoclax has IC50 of 170 nM.
Sonrotoclax (50 mg/kg) resulted in rapid tumor regression in in RS4;11 BCL2 G101V xenografts mice (TGI of 106%), but venetoclax (50 mg/kg) exhibited inadequate efficacy (TGI of 61%).
Sonrotoclax also potently inhibits other BCL2 variants, including R129L, A113G, D103Y and V156D mutants (KD values=0.04-2.1 nM).
Sonrotoclax (50 mg/kg) showed robust anti-tumor activity in the KMS-12-PE D103Y xenograft model.

物理化学性质&存储条件

分子量	890.11
分子式	C49H59N7O7S
外观性状	Solid
CAS No.
储存条件	固体粉末 -20°C 12 个月; 4°C 6 个月	配置液 -80°C 6 个月; -20°C 6 个月
Shipping
Solubility	10 mM in DMSO
Chemical Name/SMILES	N-[[4-[[(trans-4-Hydroxy-4-methylcyclohexyl)methyl]amino]-3-nitrophenyl]sulfonyl]-4-[2-[(2S)-2-[2-(1-methylethyl)phenyl]-1-pyrrolidinyl]-7-azaspiro[3.5]non-7-yl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide

参考文献

1. Liu J, et al. Blood. 2024 Jan 11:blood.2023019706.

Sonrotoclax (BGB-11417, BGB11417)

生物&药学活性

物理化学性质&存储条件

参考文献

Bulk Inquiry

* Indicates a Required FieldYour information is safe with us.

询单

Sonrotoclax (BGB-11417, BGB11417)

生物&药学活性

物理化学性质&存储条件

参考文献

Bulk Inquiry

* Indicates a Required FieldYour information is safe with us.

询单

Get Quotation Now

* Indicates a Required FieldYour information is safe with us.